Haematologica (Dec 2007)

A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy

  • Marie von Lilienfeld-Toal,
  • Corinna Hahn-Ast,
  • Hartmut Kirchner,
  • Dimitri Flieger,
  • Gottfried Dölken,
  • Axel Glasmacher

DOI
https://doi.org/10.3324/haematol.11516
Journal volume & issue
Vol. 92, no. 12

Abstract

Read online

We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.